Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label dose-escalation and expansion study of NIB101 in advanced solid tumors
jRCT2033210499Phase 1Recruiting
- Sponsor
- Noile-Immune Biotech Inc.
- Start
- Dec 2021
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NIB101 in Nonhematologic neoplasms (3 arms), sponsored by Noile-Immune Biotech Inc. Primary endpoints: Dose-limiting toxicities, Serious adverse events and 5 more. Started Dec 2021; status: recruiting.
02
Drugs
NIB101
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2033210499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210499.